Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

医学 T790米 肺癌 肿瘤科 内科学 打开标签 表皮生长因子受体 癌症 癌症研究 临床试验 吉非替尼
作者
Yuankai Shi,Xingsheng Hu,Shucai Zhang,Dongqing Lv,Lin Wu,Qitao Yu,Yiping Zhang,Li Liu,Xiang Wang,Ying Cheng,Zhiyong Ma,Hongrui Niu,Dong Wang,Jifeng Feng,Cheng Huang,Chunling Liu,Hui Zhao,Jingzhang Li,Xiaodong Zhang,Yong Jiang
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:9 (8): 829-839 被引量:127
标识
DOI:10.1016/s2213-2600(20)30455-0
摘要

Summary

Background

Furmonertinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitising EGFR and EGFR Thr790Met (T790M) mutations. This study aimed to assess the efficacy and safety of furmonertinib in patients with EGFR T790M mutated advanced non-small-cell lung cancer (NSCLC).

Methods

This study was a single-arm, open-label, phase 2b study at 46 hospitals across mainland China. Patients with locally advanced or metastatic NSCLC with centrally confirmed EGFR T790M mutations in tumour tissue who progressed after first or second generation EGFR TKIs or with primary EGFR T790M mutations received furmonertinib 80 mg orally once daily. The primary endpoint was objective response rate. Efficacy was assessed by blinded independent central review as per the Response Evaluation Criteria in Solid Tumors (version 1.1) in all patients who had measurable disease at baseline and received at least one dose of furmonertinib. Safety was assessed as per the Common Terminology Criteria for Adverse Events (version 4.03) in all patients who received at least one dose of furmonertinib with at least one safety assessment during follow-up. This study is registered with ClinicalTrials.gov (NCT03452592) and is ongoing for survival follow-up.

Findings

From Jun 4, 2018, to Dec 8, 2018, 220 patients received furmonertinib treatment. All 220 patients were included in the efficacy and safety analyses. At the data cutoff point of Jan 29, 2020, 71 (32%) patients remained on treatment. The median duration of follow-up was 9·6 months (range 0·7–19·4). The objective response rate was 74% (163 of 220 [95% CI 68–80]). Grade 3 or higher adverse events occurred in 58 (26%) patients and treatment-related grade 3 or higher adverse events occurred in 25 (11%) patients. The most common all-cause grade 3 or higher adverse events were increased γ-glutamyltransferase (five; 2%), increased aspartate aminotransferase, increased alanine aminotransferase, hyponatraemia, hypertension, pulmonary infection, hypermagnesaemia, and pericardial effusion (three each; 1%). Treatment-related diarrhoea was reported in ten (5%) patients and rashes were reported in 16 (7%) patients, all grade 1–2. Serious adverse events were reported in 52 (24%) patients, of which 12 (5%) were possibly treatment-related as evaluated by the investigator.

Interpretation

Furmonertinib has promising efficacy and an acceptable safety profile for the treatment of patients with EGFR T790M mutated NSCLC. Furmonertinib is expected to become a new treatment option after first or second generation EGFR TKIs in the Chinese population.

Funding

Shanghai Allist Pharmaceutical Technology, Ministry of Science and Technology of the People's Republic of China, and Chinese Academy of Medical Sciences.

Translation

For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
领导范儿的应助被大胆小松鼠采纳,获得10
刚刚
taobudiao完成签到,获得积分10
刚刚
赘婿的应助被认真的可冥采纳,获得30
1秒前
乐乐的应助被学术智子采纳,获得10
1秒前
LI发布了新的文献求助10
1秒前
2秒前
2秒前
喜诗糖果发布了新的文献求助10
3秒前
Lisss发布了新的文献求助10
3秒前
3秒前
3秒前
孤独百合完成签到,获得积分20
4秒前
orixero的应助被盼夏采纳,获得10
4秒前
InoriLove完成签到,获得积分10
4秒前
ice7发布了新的文献求助10
4秒前
6秒前
6秒前
高瑛键完成签到,获得积分10
6秒前
娃哈哈发布了新的文献求助10
6秒前
丑角苏发布了新的文献求助10
7秒前
大树努力要毕业完成签到,获得积分10
7秒前
飘逸的笑蓝完成签到 ,获得积分10
9秒前
王wang发布了新的文献求助10
9秒前
咸鱼完成签到,获得积分10
9秒前
haha发布了新的文献求助20
10秒前
玮玮完成签到,获得积分10
11秒前
Tuniverse_发布了新的文献求助10
11秒前
深情安青的应助被快乐越铅笔采纳,获得10
11秒前
蝴蝶结教教主完成签到,获得积分10
12秒前
完美世界的应助被二岁采纳,获得10
12秒前
水煮电吹风的应助被高瑛键采纳,获得10
12秒前
冷艳的半凡完成签到,获得积分10
12秒前
刘海留疤完成签到 ,获得积分10
14秒前
科研通AI2S的应助被WQ采纳,获得20
14秒前
Wx5211314完成签到,获得积分10
14秒前
14秒前
彭于晏的应助被木羽采纳,获得10
15秒前
喜诗糖果完成签到,获得积分20
15秒前
Yuelu发布了新的文献求助10
15秒前
学术蝗虫完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182178
求助须知:如何正确求助?哪些是违规求助? 9571839
关于积分的说明 21820273
捐赠科研通 7778694
什么是DOI,文献DOI怎么找? 3433632
关于科研通互助平台的介绍 2557802
邀请新用户注册赠送积分活动 2479657